Previous 10 | Next 10 |
Gainers: Organogenesis (NASDAQ:ORGO) +24%. CytomX Therapeutics (NASDAQ:CTMX) +13%. X4 Pharmaceuticals (NASDAQ:XFOR) +13%. MannKind (NASDAQ:MNKD) +10%. Allied Healthcare (NASDAQ:AHPI) +6%. Losers: Karyopharm Therapeutics (NASDAQ:KPTI) -31%. Bright Health Grou...
Intercept Pharmaceuticals (NASDAQ:ICPT), a biotech focused on non-viral liver diseases, has lost ~8% in the pre-market Wednesday after the company pushed back the timeline for a key data readout from a late-stage trial for Nonalcoholic steatohepatitis (NASH). Announcing its Q4 2021 ...
The following slide deck was published by Intercept Pharmaceuticals, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Intercept Pharmaceuticals, Inc. 2021 Q4 - Results - Earnings Call Presentation
Intercept Pharma press release (NASDAQ:ICPT): Q4 GAAP EPS of -$1.23 misses by $0.18. Revenue of $92.4M (+11.1% Y/Y) beats by $0.31M. Company provides 2022 Ocaliva net sales guidance of $375 million to $405 million and non-GAAP adjusted operating expense guidance of $360 million to $390 millio...
The shine has come off biotech stocks. For example, the exchange-traded fund SPDR S&P Biotech ETF (NYSEMKT: XBI) is down more than 20% so far in 2022, and more than 41% over the past 12 months. Biotech stocks still hold plenty of attraction, though, because the right ones can ma...
Worldwide Ocaliva® net sales of $92.4 million and $363.5 million for the fourth quarter and full year 2021, representing 11% and 16% growth over the prior year Company provides 2022 Ocaliva net sales guidance of $375 million to $405 million and non-GAAP adjusted operating exp...
Intercept Pharma (NASDAQ:ICPT) is scheduled to announce Q4 earnings results on Wednesday, Mar. 2, before market open. The consensus EPS estimate is -$0.81 and the consensus revenue estimate is $92.09M (+10.7% Y/Y). Over the last 1 year, ICPT has beaten EPS estimates 50% of the time and has be...
NEW YORK, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its fourth quarter and full year 20...
The stock market is giving investors some real healthcare bargains right now. In this Fool.com roundtable, we present bullish views on a couple of NASH stocks that have been hammered. And we give some love to an under-the-radar COVID play that is super cheap right now. Here's why our te...
The global launch of Bylvay was more successful than expected and Albireo doubled its net sales guidance for 2021. Beyond Odevixibat, Albireo was able to discover new drugs with blockbuster. Both early clinical assets address a market with a high medical need and have blockbuster ...
News, Short Squeeze, Breakout and More Instantly...
Intercept Pharmaceuticals Inc. Company Name:
ICPT Stock Symbol:
NASDAQ Market:
Intercept Pharmaceuticals Inc. Website:
MORRISTOWN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced five abs...
sNDA intended to satisfy post-marketing requirements to confirm a clinical benefit in patients with PBC Precedent-setting submission includes data from post-marketing studies COBALT and Study 401 as well as real-world evidence from a claims database and patient registries FDA has assign...
Data from two Phase 2 studies in PBC show combination of OCA + bezafibrate achieved biochemical remission (normalization of ALP, total bilirubin, GGT, ALT and AST) in 40-44% of patients in the first 12 weeks OCA 5 or 5-10 mg + bezafibrate 400 mg cohorts in both studies showed a >60% ...